Small molecule BH3-mimetics that mimic the BH3 binding domain of proapoptotic proteins such as Bad have been found to be effective inducers of apoptosis, and at least one such BH3-mimetic, ABT-199, has been entered into clinical trials for treatment of multiple myeloma, as well as for lymphomas and leukemias (Correia et al., 2015). This evidence concerns the gene BAD and plasma cell myeloma.